62348-13-4

Usage

Uses

Used in Pharmaceutical Industry:
ISOXAZOLE-5-CARBONYL CHLORIDE is used as a key intermediate in the synthesis of various pharmaceutical compounds for the treatment of different diseases.
Used in Cancer Treatment:
ISOXAZOLE-5-CARBONYL CHLORIDE is used as a reactant in the synthesis of 1-benzhydrylpiperazine derivatives, which may be employed in the treatment of cancer. The corresponding 1-benzhydrylpiperazine derivative can potentially target and inhibit the growth of cancer cells, offering a therapeutic option for cancer patients.
Used in Neurological and Psychiatric Illness Treatment:
ISOXAZOLE-5-CARBONYL CHLORIDE is used as a building block in the synthesis of N-Isoxazole-5-carbonyl-1,3-diphenyl-5-amino-1H-pyrazole. ISOXAZOLE-5-CARBONYL CHLORIDE can act as a potent agent in the treatment of neurological and psychiatric illnesses, providing a new avenue for the development of effective therapeutics for these conditions.

InChI:InChI=1/C4H2ClNO2/c5-4(7)3-1-2-6-8-3/h1-2H

Upstream product

• 21169-71-1 isoxazole-5-carboxylic acid 
• 88283-10-7 5-trichloromethyl isoxazole 

Relevant academic research and scientific papers

Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles

Two series of oxazolidinone derivatives having substituted isoxazoles were synthesized and tested for antibacterial activities against several Gram-positive strains including the resistant strains of Staphylococcus and Enterococcus, such as MRSA, CRSA, MSSA and VRE. Some of them showed in vitro activities (MIC) comparable or superior to the reference compound vancomycin.

Synthesis and structure-activity relationships of fused imidazopyridines: A new series of benzodiazepine receptor ligands

2-Arylimidazo[4,5-c]quinolines and analogous fused imidazopyridines were synthesized and evaluated as benzodiazepine receptor ligands. Affinity to the receptors was greatly affected by the bulkiness of the aryl group at the 2- position, compared to the pyrazoloquinolines such as CGS-9896. Derivatives with an isoxazole moiety at the 2-position showed high binding affinity and in vivo activity. In the imidazo[4,5-c]quinoline series, substitution at the 6-position decreased or abolished activity. Most derivatives with an unsubstituted isoxazolyl group showed antagonist or inverse agonist activity except for the 7-halo analogues, which exhibited agonist activity. On the other hand, 5-methylisoxazol-3-yl or 3-methylisoxazol-5-yl derivatives generally exhibited agonist activity. A similar substitution effect on the isoxazole moiety was observed in the imidazopyridines fused with a nonaromatic ring. From the detailed pharmacological evaluation, S-8510, 2- (3-isoxazolyl)-3,6,7,9-tetrahydroimidazo[4,5-d]pyrano[4,3-b]pyridine monophosphate, possessing weak inverse agonist activity was selected as a therapeutic candidate for the treatment of some symptoms of senile dementia.